The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Adrenoleukodystrophy Drugs Market Insights and Forecast to 2028
Synopsis
Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).
Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.
There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.
Market Analysis and Insights: Global Adrenoleukodystrophy Drugs Market
Due to the COVID-19 pandemic, the global Adrenoleukodystrophy Drugs market size is estimated to be worth US$ 396.1 million in 2022 and is forecast to a readjusted size of US$ 960 million by 2028 with a CAGR of 15.9% during the review period. Fully considering the economic change by this health crisis, Hormone Replacement accounting for % of the Adrenoleukodystrophy Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Childhood Cerebral ALD segment is altered to an % CAGR throughout this forecast period.
By region, North America has the highest share of revenue, exceeding 60 percent in 2019.
Global Adrenoleukodystrophy Drugs Scope and Segment
Adrenoleukodystrophy Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Adrenoleukodystrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Hormone Replacement
Transplant
Others
Segment by Application
Childhood Cerebral ALD
Adrenomyeloneuropathy (AMN)
Addison-only
Others
By Company
Bluebird Bio Inc
NeuroVia, Inc.
Orpheris, Inc.
Minoryx
MedDay Pharmaceuticals
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).
Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.
There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.
Market Analysis and Insights: Global Adrenoleukodystrophy Drugs Market
Due to the COVID-19 pandemic, the global Adrenoleukodystrophy Drugs market size is estimated to be worth US$ 396.1 million in 2022 and is forecast to a readjusted size of US$ 960 million by 2028 with a CAGR of 15.9% during the review period. Fully considering the economic change by this health crisis, Hormone Replacement accounting for % of the Adrenoleukodystrophy Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Childhood Cerebral ALD segment is altered to an % CAGR throughout this forecast period.
By region, North America has the highest share of revenue, exceeding 60 percent in 2019.
Global Adrenoleukodystrophy Drugs Scope and Segment
Adrenoleukodystrophy Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Adrenoleukodystrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Hormone Replacement
Transplant
Others
Segment by Application
Childhood Cerebral ALD
Adrenomyeloneuropathy (AMN)
Addison-only
Others
By Company
Bluebird Bio Inc
NeuroVia, Inc.
Orpheris, Inc.
Minoryx
MedDay Pharmaceuticals
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Index1 Study Coverage
1.1 Adrenoleukodystrophy Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Adrenoleukodystrophy Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Hormone Replacement
1.2.3 Transplant
1.2.4 Others
1.3 Market by Application
1.3.1 Global Adrenoleukodystrophy Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Childhood Cerebral ALD
1.3.3 Adrenomyeloneuropathy (AMN)
1.3.4 Addison-only
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Adrenoleukodystrophy Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Adrenoleukodystrophy Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Adrenoleukodystrophy Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Adrenoleukodystrophy Drugs Sales by Region
2.4.1 Global Adrenoleukodystrophy Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Adrenoleukodystrophy Drugs by Region (2023-2028)
2.5 Global Adrenoleukodystrophy Drugs Revenue by Region
2.5.1 Global Adrenoleukodystrophy Drugs Revenue by Region (2017-2022)
2.5.2 Global Adrenoleukodystrophy Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Adrenoleukodystrophy Drugs Sales by Manufacturers
3.1.1 Global Top Adrenoleukodystrophy Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Adrenoleukodystrophy Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Adrenoleukodystrophy Drugs in 2021
3.2 Global Adrenoleukodystrophy Drugs Revenue by Manufacturers
3.2.1 Global Adrenoleukodystrophy Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Adrenoleukodystrophy Drugs Revenue in 2021
3.3 Global Adrenoleukodystrophy Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Adrenoleukodystrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Adrenoleukodystrophy Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Adrenoleukodystrophy Drugs Sales by Type
4.1.1 Global Adrenoleukodystrophy Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Adrenoleukodystrophy Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Adrenoleukodystrophy Drugs Sales Market Share by Type (2017-2028)
4.2 Global Adrenoleukodystrophy Drugs Revenue by Type
4.2.1 Global Adrenoleukodystrophy Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Adrenoleukodystrophy Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Adrenoleukodystrophy Drugs Price by Type
4.3.1 Global Adrenoleukodystrophy Drugs Price by Type (2017-2022)
4.3.2 Global Adrenoleukodystrophy Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Adrenoleukodystrophy Drugs Sales by Application
5.1.1 Global Adrenoleukodystrophy Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Adrenoleukodystrophy Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Adrenoleukodystrophy Drugs Sales Market Share by Application (2017-2028)
5.2 Global Adrenoleukodystrophy Drugs Revenue by Application
5.2.1 Global Adrenoleukodystrophy Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Adrenoleukodystrophy Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Adrenoleukodystrophy Drugs Price by Application
5.3.1 Global Adrenoleukodystrophy Drugs Price by Application (2017-2022)
5.3.2 Global Adrenoleukodystrophy Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Adrenoleukodystrophy Drugs Market Size by Type
6.1.1 North America Adrenoleukodystrophy Drugs Sales by Type (2017-2028)
6.1.2 North America Adrenoleukodystrophy Drugs Revenue by Type (2017-2028)
6.2 North America Adrenoleukodystrophy Drugs Market Size by Application
6.2.1 North America Adrenoleukodystrophy Drugs Sales by Application (2017-2028)
6.2.2 North America Adrenoleukodystrophy Drugs Revenue by Application (2017-2028)
6.3 North America Adrenoleukodystrophy Drugs Market Size by Country
6.3.1 North America Adrenoleukodystrophy Drugs Sales by Country (2017-2028)
6.3.2 North America Adrenoleukodystrophy Drugs Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Adrenoleukodystrophy Drugs Market Size by Type
7.1.1 Europe Adrenoleukodystrophy Drugs Sales by Type (2017-2028)
7.1.2 Europe Adrenoleukodystrophy Drugs Revenue by Type (2017-2028)
7.2 Europe Adrenoleukodystrophy Drugs Market Size by Application
7.2.1 Europe Adrenoleukodystrophy Drugs Sales by Application (2017-2028)
7.2.2 Europe Adrenoleukodystrophy Drugs Revenue by Application (2017-2028)
7.3 Europe Adrenoleukodystrophy Drugs Market Size by Country
7.3.1 Europe Adrenoleukodystrophy Drugs Sales by Country (2017-2028)
7.3.2 Europe Adrenoleukodystrophy Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Adrenoleukodystrophy Drugs Market Size by Type
8.1.1 Asia Pacific Adrenoleukodystrophy Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Adrenoleukodystrophy Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Adrenoleukodystrophy Drugs Market Size by Application
8.2.1 Asia Pacific Adrenoleukodystrophy Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Adrenoleukodystrophy Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Adrenoleukodystrophy Drugs Market Size by Region
8.3.1 Asia Pacific Adrenoleukodystrophy Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Adrenoleukodystrophy Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Adrenoleukodystrophy Drugs Market Size by Type
9.1.1 Latin America Adrenoleukodystrophy Drugs Sales by Type (2017-2028)
9.1.2 Latin America Adrenoleukodystrophy Drugs Revenue by Type (2017-2028)
9.2 Latin America Adrenoleukodystrophy Drugs Market Size by Application
9.2.1 Latin America Adrenoleukodystrophy Drugs Sales by Application (2017-2028)
9.2.2 Latin America Adrenoleukodystrophy Drugs Revenue by Application (2017-2028)
9.3 Latin America Adrenoleukodystrophy Drugs Market Size by Country
9.3.1 Latin America Adrenoleukodystrophy Drugs Sales by Country (2017-2028)
9.3.2 Latin America Adrenoleukodystrophy Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Adrenoleukodystrophy Drugs Market Size by Type
10.1.1 Middle East and Africa Adrenoleukodystrophy Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Adrenoleukodystrophy Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Adrenoleukodystrophy Drugs Market Size by Application
10.2.1 Middle East and Africa Adrenoleukodystrophy Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Adrenoleukodystrophy Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Adrenoleukodystrophy Drugs Market Size by Country
10.3.1 Middle East and Africa Adrenoleukodystrophy Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Adrenoleukodystrophy Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Bluebird Bio Inc
11.1.1 Bluebird Bio Inc Corporation Information
11.1.2 Bluebird Bio Inc Overview
11.1.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Bluebird Bio Inc Adrenoleukodystrophy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bluebird Bio Inc Recent Developments
11.2 NeuroVia, Inc.
11.2.1 NeuroVia, Inc. Corporation Information
11.2.2 NeuroVia, Inc. Overview
11.2.3 NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 NeuroVia, Inc. Adrenoleukodystrophy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 NeuroVia, Inc. Recent Developments
11.3 Orpheris, Inc.
11.3.1 Orpheris, Inc. Corporation Information
11.3.2 Orpheris, Inc. Overview
11.3.3 Orpheris, Inc. Adrenoleukodystrophy Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Orpheris, Inc. Adrenoleukodystrophy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Orpheris, Inc. Recent Developments
11.4 Minoryx
11.4.1 Minoryx Corporation Information
11.4.2 Minoryx Overview
11.4.3 Minoryx Adrenoleukodystrophy Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Minoryx Adrenoleukodystrophy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Minoryx Recent Developments
11.5 MedDay Pharmaceuticals
11.5.1 MedDay Pharmaceuticals Corporation Information
11.5.2 MedDay Pharmaceuticals Overview
11.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 MedDay Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Adrenoleukodystrophy Drugs Industry Chain Analysis
12.2 Adrenoleukodystrophy Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Adrenoleukodystrophy Drugs Production Mode & Process
12.4 Adrenoleukodystrophy Drugs Sales and Marketing
12.4.1 Adrenoleukodystrophy Drugs Sales Channels
12.4.2 Adrenoleukodystrophy Drugs Distributors
12.5 Adrenoleukodystrophy Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Adrenoleukodystrophy Drugs Industry Trends
13.2 Adrenoleukodystrophy Drugs Market Drivers
13.3 Adrenoleukodystrophy Drugs Market Challenges
13.4 Adrenoleukodystrophy Drugs Market Restraints
14 Key Findings in The Global Adrenoleukodystrophy Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of TablesList of Tables
Table 1. Global Adrenoleukodystrophy Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Hormone Replacement
Table 3. Major Manufacturers of Transplant
Table 4. Major Manufacturers of Others
Table 5. Global Adrenoleukodystrophy Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Adrenoleukodystrophy Drugs Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Adrenoleukodystrophy Drugs Sales by Region (2017-2022) & (K Units)
Table 8. Global Adrenoleukodystrophy Drugs Sales Market Share by Region (2017-2022)
Table 9. Global Adrenoleukodystrophy Drugs Sales by Region (2023-2028) & (K Units)
Table 10. Global Adrenoleukodystrophy Drugs Sales Market Share by Region (2023-2028)
Table 11. Global Adrenoleukodystrophy Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Adrenoleukodystrophy Drugs Revenue Market Share by Region (2017-2022)
Table 13. Global Adrenoleukodystrophy Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global Adrenoleukodystrophy Drugs Revenue Market Share by Region (2023-2028)
Table 15. Global Adrenoleukodystrophy Drugs Sales by Manufacturers (2017-2022) & (K Units)
Table 16. Global Adrenoleukodystrophy Drugs Sales Share by Manufacturers (2017-2022)
Table 17. Global Adrenoleukodystrophy Drugs Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global Adrenoleukodystrophy Drugs Revenue Share by Manufacturers (2017-2022)
Table 19. Adrenoleukodystrophy Drugs Price by Manufacturers (2017-2022) &(US$/Unit)
Table 20. Global Adrenoleukodystrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Adrenoleukodystrophy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Drugs as of 2021)
Table 22. Adrenoleukodystrophy Drugs Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Adrenoleukodystrophy Drugs Product Offered
Table 24. Date of Manufacturers Enter into Adrenoleukodystrophy Drugs Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Adrenoleukodystrophy Drugs Sales by Type (2017-2022) & (K Units)
Table 27. Global Adrenoleukodystrophy Drugs Sales by Type (2023-2028) & (K Units)
Table 28. Global Adrenoleukodystrophy Drugs Sales Share by Type (2017-2022)
Table 29. Global Adrenoleukodystrophy Drugs Sales Share by Type (2023-2028)
Table 30. Global Adrenoleukodystrophy Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global Adrenoleukodystrophy Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global Adrenoleukodystrophy Drugs Revenue Share by Type (2017-2022)
Table 33. Global Adrenoleukodystrophy Drugs Revenue Share by Type (2023-2028)
Table 34. Adrenoleukodystrophy Drugs Price by Type (2017-2022) & (US$/Unit)
Table 35. Global Adrenoleukodystrophy Drugs Price Forecast by Type (2023-2028) & (US$/Unit)
Table 36. Global Adrenoleukodystrophy Drugs Sales by Application (2017-2022) & (K Units)
Table 37. Global Adrenoleukodystrophy Drugs Sales by Application (2023-2028) & (K Units)
Table 38. Global Adrenoleukodystrophy Drugs Sales Share by Application (2017-2022)
Table 39. Global Adrenoleukodystrophy Drugs Sales Share by Application (2023-2028)
Table 40. Global Adrenoleukodystrophy Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 41. Global Adrenoleukodystrophy Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 42. Global Adrenoleukodystrophy Drugs Revenue Share by Application (2017-2022)
Table 43. Global Adrenoleukodystrophy Drugs Revenue Share by Application (2023-2028)
Table 44. Adrenoleukodystrophy Drugs Price by Application (2017-2022) & (US$/Unit)
Table 45. Global Adrenoleukodystrophy Drugs Price Forecast by Application (2023-2028) & (US$/Unit)
Table 46. North America Adrenoleukodystrophy Drugs Sales by Type (2017-2022) & (K Units)
Table 47. North America Adrenoleukodystrophy Drugs Sales by Type (2023-2028) & (K Units)
Table 48. North America Adrenoleukodystrophy Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America Adrenoleukodystrophy Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America Adrenoleukodystrophy Drugs Sales by Application (2017-2022) & (K Units)
Table 51. North America Adrenoleukodystrophy Drugs Sales by Application (2023-2028) & (K Units)
Table 52. North America Adrenoleukodystrophy Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 53. North America Adrenoleukodystrophy Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 54. North America Adrenoleukodystrophy Drugs Sales by Country (2017-2022) & (K Units)
Table 55. North America Adrenoleukodystrophy Drugs Sales by Country (2023-2028) & (K Units)
Table 56. North America Adrenoleukodystrophy Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America Adrenoleukodystrophy Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe Adrenoleukodystrophy Drugs Sales by Type (2017-2022) & (K Units)
Table 59. Europe Adrenoleukodystrophy Drugs Sales by Type (2023-2028) & (K Units)
Table 60. Europe Adrenoleukodystrophy Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe Adrenoleukodystrophy Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe Adrenoleukodystrophy Drugs Sales by Application (2017-2022) & (K Units)
Table 63. Europe Adrenoleukodystrophy Drugs Sales by Application (2023-2028) & (K Units)
Table 64. Europe Adrenoleukodystrophy Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 65. Europe Adrenoleukodystrophy Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 66. Europe Adrenoleukodystrophy Drugs Sales by Country (2017-2022) & (K Units)
Table 67. Europe Adrenoleukodystrophy Drugs Sales by Country (2023-2028) & (K Units)
Table 68. Europe Adrenoleukodystrophy Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe Adrenoleukodystrophy Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific Adrenoleukodystrophy Drugs Sales by Type (2017-2022) & (K Units)
Table 71. Asia Pacific Adrenoleukodystrophy Drugs Sales by Type (2023-2028) & (K Units)
Table 72. Asia Pacific Adrenoleukodystrophy Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific Adrenoleukodystrophy Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific Adrenoleukodystrophy Drugs Sales by Application (2017-2022) & (K Units)
Table 75. Asia Pacific Adrenoleukodystrophy Drugs Sales by Application (2023-2028) & (K Units)
Table 76. Asia Pacific Adrenoleukodystrophy Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 77. Asia Pacific Adrenoleukodystrophy Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 78. Asia Pacific Adrenoleukodystrophy Drugs Sales by Region (2017-2022) & (K Units)
Table 79. Asia Pacific Adrenoleukodystrophy Drugs Sales by Region (2023-2028) & (K Units)
Table 80. Asia Pacific Adrenoleukodystrophy Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 81. Asia Pacific Adrenoleukodystrophy Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 82. Latin America Adrenoleukodystrophy Drugs Sales by Type (2017-2022) & (K Units)
Table 83. Latin America Adrenoleukodystrophy Drugs Sales by Type (2023-2028) & (K Units)
Table 84. Latin America Adrenoleukodystrophy Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 85. Latin America Adrenoleukodystrophy Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 86. Latin America Adrenoleukodystrophy Drugs Sales by Application (2017-2022) & (K Units)
Table 87. Latin America Adrenoleukodystrophy Drugs Sales by Application (2023-2028) & (K Units)
Table 88. Latin America Adrenoleukodystrophy Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 89. Latin America Adrenoleukodystrophy Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 90. Latin America Adrenoleukodystrophy Drugs Sales by Country (2017-2022) & (K Units)
Table 91. Latin America Adrenoleukodystrophy Drugs Sales by Country (2023-2028) & (K Units)
Table 92. Latin America Adrenoleukodystrophy Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 93. Latin America Adrenoleukodystrophy Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 94. Middle East and Africa Adrenoleukodystrophy Drugs Sales by Type (2017-2022) & (K Units)
Table 95. Middle East and Africa Adrenoleukodystrophy Drugs Sales by Type (2023-2028) & (K Units)
Table 96. Middle East and Africa Adrenoleukodystrophy Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 97. Middle East and Africa Adrenoleukodystrophy Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 98. Middle East and Africa Adrenoleukodystrophy Drugs Sales by Application (2017-2022) & (K Units)
Table 99. Middle East and Africa Adrenoleukodystrophy Drugs Sales by Application (2023-2028) & (K Units)
Table 100. Middle East and Africa Adrenoleukodystrophy Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 101. Middle East and Africa Adrenoleukodystrophy Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 102. Middle East and Africa Adrenoleukodystrophy Drugs Sales by Country (2017-2022) & (K Units)
Table 103. Middle East and Africa Adrenoleukodystrophy Drugs Sales by Country (2023-2028) & (K Units)
Table 104. Middle East and Africa Adrenoleukodystrophy Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa Adrenoleukodystrophy Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 106. Bluebird Bio Inc Corporation Information
Table 107. Bluebird Bio Inc Description and Major Businesses
Table 108. Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 109. Bluebird Bio Inc Adrenoleukodystrophy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. Bluebird Bio Inc Recent Developments
Table 111. NeuroVia, Inc. Corporation Information
Table 112. NeuroVia, Inc. Description and Major Businesses
Table 113. NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 114. NeuroVia, Inc. Adrenoleukodystrophy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. NeuroVia, Inc. Recent Developments
Table 116. Orpheris, Inc. Corporation Information
Table 117. Orpheris, Inc. Description and Major Businesses
Table 118. Orpheris, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 119. Orpheris, Inc. Adrenoleukodystrophy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Orpheris, Inc. Recent Developments
Table 121. Minoryx Corporation Information
Table 122. Minoryx Description and Major Businesses
Table 123. Minoryx Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 124. Minoryx Adrenoleukodystrophy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Minoryx Recent Developments
Table 126. MedDay Pharmaceuticals Corporation Information
Table 127. MedDay Pharmaceuticals Description and Major Businesses
Table 128. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 129. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. MedDay Pharmaceuticals Recent Developments
Table 131. Key Raw Materials Lists
Table 132. Raw Materials Key Suppliers Lists
Table 133. Adrenoleukodystrophy Drugs Distributors List
Table 134. Adrenoleukodystrophy Drugs Customers List
Table 135. Adrenoleukodystrophy Drugs Market Trends
Table 136. Adrenoleukodystrophy Drugs Market Drivers
Table 137. Adrenoleukodystrophy Drugs Market Challenges
Table 138. Adrenoleukodystrophy Drugs Market Restraints
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Adrenoleukodystrophy Drugs Product Picture
Figure 3. Global Adrenoleukodystrophy Drugs Market Share by Type in 2021 & 2028
Figure 3. Hormone Replacement Product Picture
Figure 4. Transplant Product Picture
Figure 5. Others Product Picture
Figure 6. Global Adrenoleukodystrophy Drugs Market Share by Application in 2021 & 2028
Figure 7. Childhood Cerebral ALD
Figure 8. Adrenomyeloneuropathy (AMN)
Figure 9. Addison-only
Figure 10. Others
Figure 11. Adrenoleukodystrophy Drugs Report Years Considered
Figure 12. Global Adrenoleukodystrophy Drugs Sales 2017-2028 (K Units)
Figure 13. Global Adrenoleukodystrophy Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Adrenoleukodystrophy Drugs Revenue 2017-2028 (US$ Million)
Figure 15. Global Adrenoleukodystrophy Drugs Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 16. Global Adrenoleukodystrophy Drugs Sales Market Share by Region (2017-2022)
Figure 17. Global Adrenoleukodystrophy Drugs Sales Market Share by Region (2023-2028)
Figure 18. North America Adrenoleukodystrophy Drugs Sales YoY (2017-2028) & (K Units)
Figure 19. North America Adrenoleukodystrophy Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Europe Adrenoleukodystrophy Drugs Sales YoY (2017-2028) & (K Units)
Figure 21. Europe Adrenoleukodystrophy Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Asia-Pacific Adrenoleukodystrophy Drugs Sales YoY (2017-2028) & (K Units)
Figure 23. Asia-Pacific Adrenoleukodystrophy Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Latin America Adrenoleukodystrophy Drugs Sales YoY (2017-2028) & (K Units)
Figure 25. Latin America Adrenoleukodystrophy Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Middle East & Africa Adrenoleukodystrophy Drugs Sales YoY (2017-2028) & (K Units)
Figure 27. Middle East & Africa Adrenoleukodystrophy Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 28. The Adrenoleukodystrophy Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 29. The Top 5 and 10 Largest Manufacturers of Adrenoleukodystrophy Drugs in the World: Market Share by Adrenoleukodystrophy Drugs Revenue in 2021
Figure 30. Global Adrenoleukodystrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 31. Global Adrenoleukodystrophy Drugs Sales Market Share by Type (2017-2028)
Figure 32. Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2017-2028)
Figure 33. Global Adrenoleukodystrophy Drugs Sales Market Share by Application (2017-2028)
Figure 34. Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2017-2028)
Figure 35. North America Adrenoleukodystrophy Drugs Sales Market Share by Type (2017-2028)
Figure 36. North America Adrenoleukodystrophy Drugs Revenue Market Share by Type (2017-2028)
Figure 37. North America Adrenoleukodystrophy Drugs Sales Market Share by Application (2017-2028)
Figure 38. North America Adrenoleukodystrophy Drugs Revenue Market Share by Application (2017-2028)
Figure 39. North America Adrenoleukodystrophy Drugs Sales Share by Country (2017-2028)
Figure 40. North America Adrenoleukodystrophy Drugs Revenue Share by Country (2017-2028)
Figure 41. U.S. Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 42. Canada Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 43. Europe Adrenoleukodystrophy Drugs Sales Market Share by Type (2017-2028)
Figure 44. Europe Adrenoleukodystrophy Drugs Revenue Market Share by Type (2017-2028)
Figure 45. Europe Adrenoleukodystrophy Drugs Sales Market Share by Application (2017-2028)
Figure 46. Europe Adrenoleukodystrophy Drugs Revenue Market Share by Application (2017-2028)
Figure 47. Europe Adrenoleukodystrophy Drugs Sales Share by Country (2017-2028)
Figure 48. Europe Adrenoleukodystrophy Drugs Revenue Share by Country (2017-2028)
Figure 49. Germany Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 50. France Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 51. U.K. Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 52. Italy Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 53. Russia Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 54. Asia Pacific Adrenoleukodystrophy Drugs Sales Market Share by Type (2017-2028)
Figure 55. Asia Pacific Adrenoleukodystrophy Drugs Revenue Market Share by Type (2017-2028)
Figure 56. Asia Pacific Adrenoleukodystrophy Drugs Sales Market Share by Application (2017-2028)
Figure 57. Asia Pacific Adrenoleukodystrophy Drugs Revenue Market Share by Application (2017-2028)
Figure 58. Asia Pacific Adrenoleukodystrophy Drugs Sales Share by Region (2017-2028)
Figure 59. Asia Pacific Adrenoleukodystrophy Drugs Revenue Share by Region (2017-2028)
Figure 60. China Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 61. Japan Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 62. South Korea Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 63. India Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 64. Australia Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 65. Taiwan Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 66. Indonesia Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 67. Thailand Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 68. Malaysia Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 69. Philippines Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 70. Latin America Adrenoleukodystrophy Drugs Sales Market Share by Type (2017-2028)
Figure 71. Latin America Adrenoleukodystrophy Drugs Revenue Market Share by Type (2017-2028)
Figure 72. Latin America Adrenoleukodystrophy Drugs Sales Market Share by Application (2017-2028)
Figure 73. Latin America Adrenoleukodystrophy Drugs Revenue Market Share by Application (2017-2028)
Figure 74. Latin America Adrenoleukodystrophy Drugs Sales Share by Country (2017-2028)
Figure 75. Latin America Adrenoleukodystrophy Drugs Revenue Share by Country (2017-2028)
Figure 76. Mexico Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 77. Brazil Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 78. Argentina Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 79. Middle East and Africa Adrenoleukodystrophy Drugs Sales Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Adrenoleukodystrophy Drugs Revenue Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Adrenoleukodystrophy Drugs Sales Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Adrenoleukodystrophy Drugs Revenue Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Adrenoleukodystrophy Drugs Sales Share by Country (2017-2028)
Figure 84. Middle East and Africa Adrenoleukodystrophy Drugs Revenue Share by Country (2017-2028)
Figure 85. Turkey Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 86. Saudi Arabia Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 87. UAE Adrenoleukodystrophy Drugs Revenue (2017-2028) & (US$ Million)
Figure 88. Adrenoleukodystrophy Drugs Value Chain
Figure 89. Adrenoleukodystrophy Drugs Production Process
Figure 90. Channels of Distribution
Figure 91. Distributors Profiles
Figure 92. Bottom-up and Top-down Approaches for This Report
Figure 93. Data Triangulation
Figure 94. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
